Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692642 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL302999 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL302998 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL304309 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL4344462 | 0.99 | ADRB3 (0.98) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Water SCHEMBL15421412 | 0.98 | ADRB3 (0.96) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL6539097 | 0.93 | ADRB3 (0.87) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| SCHEMBL6539102 | 0.93 | ADRB3 (0.87) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Hydrochloric Acid SCHEMBL6540037 | 0.93 | ADRB3 (0.86) | ADRB3ADRB2ADRB1CYP2D6ADRA1D | |
| Hydrochloric Acid SCHEMBL6540028 | 0.93 | ADRB3 (0.86) | ADRB3ADRB2ADRB1CYP2D6ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374557-A1 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-14 | — | — | US | claimed |
| US-20240301022-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | UNIV ASTON (GB) | 2024-09-12 | — | — | US | claimed |
| US-20240148701-A1 | WOULD HEALING METHODS | UNIV SYDNEY (AU) | 2024-05-09 | — | — | US | claimed |
| US-20240000888-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | ASTON UNIVERSITY (GB) | 2024-01-04 | — | — | US | claimed |
| EP-4294390-A1 | WOUND HEALING METHODS | The University Of Sydney (AU) | 2023-12-27 | — | — | EP | claimed |
| US-20230210826-A1 | DRUG COMBINATION FOR TREATING OBESITY | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2023-07-06 | — | — | US | claimed |
| WO-2023028602-A1 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| WO-2022174309-A1 | WOUND HEALING METHODS | THE UNIVERSITY OF SYDNEY (AU) | 2022-08-25 | — | — | WO | claimed |
| CN-114028370-A | Composition with effects of preventing and treating obesity and related diseases and application thereof | 中山大学 | 2022-02-11 | — | — | CN | claimed |
| EP-2891490-B1 | BETA-3 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE | FUNDACION CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III CNIC (ES) | 2020-12-09 | — | — | EP | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-5977374-A | 5-(4-hydroxy-OR 4-acetoxy-benzyl)-3- triphenylmethylthiazolidine-2,4-dione and method for producing same | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| US-5635534-A | 1-PHENYL-2-(2-PHENYLOXY OR THIO)-1-METHYLETHYL)AMINOETHANOL DERIVATIVES; ALDOSE REDUCTASE INHIBITORS; NONTOXIC; ANTIDIABETIC,-OBESITY,-LIPEMIC AND HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5576340-A | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-11-19 | — | — | US | disclosed |
| US-5245053-A | Resolution of diastereoisomers, reaction with Mosher's acid hypoglycemic agent, diabetes | AMERICAN CYANAMID COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ADRB3 131/4885ADRB2 177/4885ADRB1 161/4885 |
| US-20240148701-A1 | WOULD HEALING METHODS | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.